Pancreatic cancer enhances HER2 signaling through DUSP6 to circumvent therapeutic MAPK inhibition.

被引：0
|
作者：
Bulle, Ashenafi Shiferaw [1 ,2 ]
Seehar, Kuljeet [1 ,2 ]
Bansod, Sapana [1 ,2 ]
Chen, Yali [1 ,2 ]
Hung-Po, Chen [1 ,2 ]
Dodhiawala, Paarth B. [1 ,2 ]
Li, Lin [1 ,2 ]
Somani, Vikas [1 ,2 ]
Mudd, Jacqueline [1 ,2 ]
Fields, Ryan C. [1 ,2 ]
Knoerzer, Deborah [3 ]
Wang-Gillam, Andrea [1 ,2 ]
Kian-Huat, Lim [1 ,2 ]
机构：
[1] Washington Univ, Sch Med, Barnes Jewish Hosp, St Louis, MO USA
[2] Washington Univ, Sch Med, Alvin J Siteman Comprehens Canc Ctr, St Louis, MO USA
[3] 23BioMed Valley Discoveries, Kansas City, MO USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
DS-8201a; DUSP6; HER2; KRAS; ulixertinib; pancreatic ductal adenocarcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5333
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pancreatic cancer musters HER2 signaling through DUSP6 to circumvent therapeutic MAPK inhibition.
    Bulle, Ashenafi Shiferaw
    CANCER RESEARCH, 2021, 81 (13)
  • [2] BOP1 Promotes Prostate Cancer through the DUSP6/MAPK Pathway
    Wu, Xiaoqing
    Jing, Zheng
    Huang, Tianpu
    Jing, Yongsheng
    ARCHIVOS ESPANOLES DE UROLOGIA, 2023, 76 (06): : 445 - 453
  • [3] DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+breast cancer
    Momeny, Majid
    Tienhaara, Mari
    Sharma, Mukund
    Chakroborty, Deepankar
    Varjus, Roosa
    Takala, Iina
    Merisaari, Joni
    Padzik, Artur
    Vogt, Andreas
    Paatero, Ilkka
    Elenius, Klaus
    Laajala, Teemu D.
    Kurppa, Kari J.
    Westermarck, Jukka
    EMBO MOLECULAR MEDICINE, 2024, 16 (07) : 1603 - 1629
  • [4] Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
    Marin, Arnaldo
    Al Mamun, Abdullah
    Patel, Hima
    Akamatsu, Hiroaki
    Ye, Dan
    Sudhan, Dhivya R.
    Eli, Lisa
    Marcelain, Katherine
    Brown, Benjamin P.
    Meiler, Jens
    Arteaga, Carlos L.
    Hanker, Ariella B.
    CANCER RESEARCH, 2023, 83 (18) : 3145 - 3158
  • [5] EGFR and HER2 inhibition in pancreatic cancer
    Naomi Walsh
    Susan Kennedy
    AnneMarie Larkin
    Brendan Corkery
    Lorraine O’Driscoll
    Martin Clynes
    John Crown
    Norma O’Donovan
    Investigational New Drugs, 2013, 31 : 558 - 566
  • [6] EGFR and HER2 inhibition in pancreatic cancer
    Walsh, Naomi
    Kennedy, Susan
    Larkin, AnneMarie
    Corkery, Brendan
    O'Driscoll, Lorraine
    Clynes, Martin
    Crown, John
    O'Donovan, Norma
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 558 - 566
  • [7] Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway
    Gao, Yan
    Li, Hui
    Hang, Qing
    Li, Yuan
    Wang, Tongxia
    Huang, Cuiyu
    Mao, Yiqing
    Wang, Xi
    Zhang, Qun
    Tian, Junrui
    Irwin, David M.
    Tang, Huanran
    Guo, Hongyan
    JOURNAL OF CANCER, 2020, 11 (11): : 3151 - 3164
  • [8] OVEREXPRESSION OF DUSP6 ENHANCES CHEMOTHERAPY-RESISTANCE OF OVARIAN EPITHELIAL CANCER BY REGULATING THE ERK SIGNALING PATHWAY
    Gao, Y.
    Li, H.
    Han, Q.
    Li, Y.
    Wang, T.
    Huang, C.
    Mao, Y.
    Wang, X.
    Zhang, Q.
    Tian, J.
    Irwin, D. M.
    Tan, H.
    Guo, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A463 - A463
  • [9] A HER3/DUSP6 loop determines sensitivity to HER2-targeted therapies in breast cancer
    Momeny, M.
    Merisaari, J.
    Padzik, A.
    Tienhaara, M.
    Aspelin, W.
    Westermarck, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1093 - S1093
  • [10] Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6/MAPK signaling
    Huang, Shoucheng
    Huang, Ping
    Wu, Huazhang
    Wang, Song
    Liu, Guodong
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2021, 59 (04) : 291 - 301
12345